[ December 11, 2008 ]
“SCYNEXIS believes that this collaborative project approach with DNDi can play an important role in improving the discovery and development of new therapies for neglected diseases,” said SCYNEXIS President & CEO Yves Ribeill. “We are pleased with the progress this alliance has achieved to date and look forward to continuing to apply our expertise in drug discovery and development to identify new drug candidates to treat sleeping sickness.”
[ December 11, 2008 ]
[ New Orleans, USA; Paris, France; Geneva, Switzerland – December 9, 2008]
Pivotal Phase III clinical trial results conclusively show that Nifurtimox-Eflornithine Combination Therapy (NECT) is well tolerated and effective against the advanced stage of T. b. gambiense sleeping sickness, a fatal disease that threatens 60 million people in sub-Saharan Africa.
Significant Step towards Expanded Global Access to Malaria Treatment
[ Paris, France, and Geneva, Switzerland – October 16, 2008]
Sanofi-aventis and the non-profit Drugs for Neglected Diseases initiative (DNDi) welcome the approval, by the World Health Organization (WHO) Prequalification of Medicines Program, of Coarsucam™ / Artesunate Amodiaquine Winthrop® (“ASAQ”), the first fixed-dose combination of the two antimalarial compounds, artesunate (AS) and amodiaquine (AQ).
[ New Dehli – October 13, 2008]
More than 100 scientists and researchers convene in New Delhi to discuss the present and future role of India in research and development (R&D), access, and capacity strengthening to develop and deliver new treatments needed by neglected patients.
[ Geneva; Switzerland and Recife, Brasil – July 21st, 2008]
An agreement between Drugs for Neglected Diseases initiative (DNDi) and the Pharmaceutical Laboratory of Pernambuco (Lafepe) will deliver the first pediatric formulation of benznidazole, the most widely used drug for the treatment of Chagas disease, at cost and for worldwide distribution.
[ Paris, France, and Geneva, Switzerland – July 21st, 2008]
Sanofi-aventis and the non-profit Drugs for Neglected Diseases initiative (DNDi) welcome the agreement announced by Clinton Foundation HIV/AIDS Initiative (CHAI) to reduce the volatility and the price levels of Artemisinin-based Combination Therapies (ACT).
[ Geneva – June 30, 2008 ]
Immediately following the Drugs for Neglected Diseases initiative (DNDi) Stakeholders’ Meeting on June 26, 2008, and in advance of the upcoming 2008 G8 Summit in Japan, DNDi released a statement endorsed by World Health Organization (WHO) urging the G8 governments to support both control programs and research & development (R&D) initiatives for neglected tropical diseases.
[ New York – June 23, 2008 ]
More Than 150 Scientists and Researchers from Around the World Convene in New York to Mobilize R&D Resources for Neglected Diseases.
[ Paris, Geneva – June 11, 2008 ]
Today, the Paris-based Institut de Recherche pour le Développement (IRD) and DNDi announced the implementation of scientific cooperation projects for developing treatments against visceral leishmaniasis, Chagas disease, and sleeping sickness.
[ Chapel Hill, USA; Geneva, Switzerland – June 4, 2008 ]
International fight against neglected tropical diseases strengthened by collaboration between two leading public-private partnerships to further development of safe and affordable drugs to fight diseases in the least developed countries.
[ Siena, Italy; Geneva, Switzerland – May 8, 2008 ]
The University of Siena today awarded the Drugs for Neglected Diseases initiative (DNDi) with a Goodwin Award for its innovative needs-driven approach in making 2 new antimalarials available as public goods, and in engaging public and private partners worldwide, especially in neglected disease-endemic countries, to ensure that the best science is made available for those neglected patients.
[ Rio de Janeiro – April 17, 2008 ]
An innovative partnership between the Brazilian public pharmaceutical company, Farmanguinhos/Fiocruz, and the non-profit drug development organization, Drugs for Neglected Diseases initiative (DNDi), announced today that ASMQ, the new fixed-dose combination of artesunate (AS) and mefloquine (MQ), is now registered and available in Brazil.
[Português] [Español] [Français] [Italiano]
[ Madrid and Geneva – March 6, 2008 ]
Spain’s Agencia Española de Cooperación Internacional (AECI) today granted EUR 5.0 million to the Drugs for Neglected Diseases initiative (DNDi) for essential research and development (R&D) of drugs for neglected diseases such as human African trypanosomiasis, leishmaniasis, Chagas disease, and malaria.
[ Tres Cantos, Spain; Geneva, Switzerland – March 6, 2008 ]
GlaxoSmithKline (GSK) and the not-for-profit organization, Drugs for Neglected Diseases initiative (DNDi), today announced a collaborative research effort targeting neglected tropical diseases which disproportionately affect the developing world.